Valuation
- Market cap
- 393,659,000
- Revenue TTM
- $0
- Net income TTM
- $-77,590,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,646,300
- Avg volume
- 1,408,112
- Day's range
- $3.96 – $4.20
- Shares out
- 96,722,000
- Stochastic %K
- 31%
- Beta
- 0.54
- Analysts
- Strong Sell
- Price target
- $9.10
Company profile
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly kn...
Show more
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 206 4507
- Website
- https://www.rezolutebio.com
- Address
- 275 Shoreline Drive, Suite 500, Redwood City, United States
Latest news
No headlines yet.
